| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 12/11/2001 | US6329421 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| 12/11/2001 | US6329418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 12/11/2001 | US6329417 Hepatitis C inhibitor tri-pepitides |
| 12/11/2001 | US6329415 Aromatic heterocyclic compounds as antiinflammatory agents |
| 12/11/2001 | US6329402 Heterocycle-containing carboxylic acid derivative and drug containing the same |
| 12/11/2001 | US6329397 Hydroxy pipecolate hydroxamic acid derivatives |
| 12/11/2001 | US6329394 Medical use for tachykinin antagonists |
| 12/11/2001 | US6329385 Antiinflammatory agents, antiarthritic agents, viral diseases and gastrointestinal disorders |
| 12/11/2001 | US6329380 Pyrimidine benzimidizazole, pyrimidineimidazole or pyridine imidazole compounds for anticancer agents or atherosclerosis |
| 12/11/2001 | US6329379 Oligopeptides for inhibiting hepatitis |
| 12/11/2001 | US6329365 Inhibitors of interleukin-1β converting enzyme |
| 12/11/2001 | US6328994 Orally disintegrable tablets |
| 12/11/2001 | US6328993 Oral administration form for an acid liable active proton pump inhibitor |
| 12/11/2001 | US6328966 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 12/11/2001 | CA2226292C Substituted benzolactam compounds as substance p antagonists |
| 12/11/2001 | CA2117953C Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| 12/06/2001 | WO2001092534A1 Biological materials and methods for use in the prevention or treatment of infections |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092490A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092479A2 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | WO2001092332A1 Feline hepatocyte growth factor |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092282A2 Methods and compositions for treating flaviviruses and pestiviruses |
| 12/06/2001 | WO2001092267A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092241A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091748A2 Methods for prevention of ulcers and improving physiological performance |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091711A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001021605A8 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000071101A3 Methods and compounds for inhibiting amyloid deposits |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049360 Betaglycan as an inhibin receptor and uses thereof |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2411323A1 Il-8 receptor antagonists |
| 12/06/2001 | CA2410935A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410762A1 Feline hepatocyte growth factor |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410684A1 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | CA2410655A1 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | CA2410591A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2410033A1 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | CA2409617A1 2,7-naphthyridine derivatives |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/05/2001 | EP1160255A1 Monovalent antibody fragments |
| 12/05/2001 | EP1159975A2 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159974A1 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159964A2 Compositions and methods for stimulating gastrointestinal motility |
| 12/05/2001 | EP1159951A1 Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
| 12/05/2001 | EP1159457A1 T cell receptor vbeta beta-jbeta) sequence and methods for its detection |
| 12/05/2001 | EP1159455A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 12/05/2001 | EP1159420A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159291A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159284A1 33 human secreted proteins |
| 12/05/2001 | EP1159275A2 Imidazole compounds as histamine h3 ligands |
| 12/05/2001 | EP1159265A1 C-16 unsaturated fp-selective prostaglandins analogs |
| 12/05/2001 | EP1159010A1 Treatment of diarrhea caused by enteropathogenic escherichia coli |
| 12/05/2001 | EP1158996A1 Novel amide derivatives as growth hormone secretagogues |
| 12/05/2001 | EP1158988A2 Corticosteroid formulation |
| 12/05/2001 | EP1158986A1 Protease inhibitors |
| 12/05/2001 | EP1158984A1 Inhibitors of prenyl-protein transferase |
| 12/05/2001 | EP1158982A2 Inhibitors of prenyl-protein transferase |
| 12/05/2001 | EP1158963A1 Controlled-release compositions of betahistine |
| 12/05/2001 | EP1158958A1 Improved powdery pharmaceutical compositions for inhalation |
| 12/05/2001 | EP1158867A2 Pet food product with coconut endosperm fibre |
| 12/05/2001 | EP1017377B1 Use of 6, 7-substituted 2-aminotetralines for the treatment of cytokine mediated inflammatory conditions |
| 12/05/2001 | EP0937036B1 Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors |
| 12/05/2001 | EP0828724B1 Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors |
| 12/05/2001 | EP0814815A4 Poly(hydroxy acid)/polymer conjugates for skin applications |
| 12/05/2001 | EP0769056B1 NON-SPLICING VARIANTS OF gp350/220 |
| 12/05/2001 | EP0720484B1 Plant material for controlling immune responses in mammals and method for producing the material |